An independent advisory committee to the Food and Drug Administration voted Thursday to recommend a shot that protects infants from RSV by vaccinating their mothers while pregnant.
The 14-person panel unanimously recommended the shot, made by Pfizer, based on its efficacy and voted 10-4 to recommend it based on its safety.
If the shot is eventually approved by the FDA, it would be the first vaccine that confers protection against respiratory syncytial virus to babies.
“Before the pandemic, RSV was the No. 1 cause of infant hospitalization in the United States, so this is a big deal,” said Dr. Ofer Levy, the director of the Precision Vaccines Program at Boston Children’s Hospital. Levy is a temporary voting member of the FDA panel but wasn’t involved in Thursday’s vote.
0 Comments